Celiac disease products


Celiac disease affects 1% of the population and therefore is the most common chronic inflammation of the small intestine triggered by cereal gluten/gliadin uptake in genetically susceptible individuals. The gluten induced autoimmune disorder is characterized by autoantibodies to tissue transglutaminase (TG2), antibodies to deamidated gliadin and villous atrophy in the final stage.

TG2 plays a central role in celiac disease. Besides being the major autoantigen it is involved in the pathogenesis. Under certain circumstances and in distinct environments as given in the inflamed gut TG2 catalyzes deamidation of glutamine side chains in gliadin yielding glutamic acid. Deamidated gliadin is subsequently recognized by receptors of the immune system triggering celiac disease.

Related gluten induced autoimmune disorders are dermatitis herpetiformis / Morbus Duhring (autoantigen: epidermal transglutaminase, TG3).


Gluten-sensitive neurological disorders like Gluten ataxia may be accompanied by auto- antibodies to neuronal transglutaminase (TG6).
Detection of TG6-autoantibodies in human sera is possible using our ELISA-Kits E103 (anti-TG6-IgA) and E104 (anti-TG6-IgG).

New: Analytical service for measurement of TG6-autoantibodies in human serum samples

In co-operation with the medical laboratory of Prof. Dr. med. M. Kramer (board-certified clinical pathologist) in Heidelberg, Germany we provide testing services for the determination of Transglutaminase auto-antibodies in patient serum samples.

Order Sheet (English)
Bestellformular (Deutsch)

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland